The shares of the America Based Gilead Sciences Inc. GILD rose 1.09% to $66.03 Wednesday. This proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.14% to 4,208.12 and the Dow Jones Industrial Average DJIA rising 0.07% to 34,600.38. Gilead Sciences Inc. closed $13.28 short of its 52-week high ($79.31), which the company achieved on June 8th.
Gilead Sciences Inc stock outperformed some of its competitors Wednesday, as Johnson & Johnson JNJ rose 0.40% to $166.20, Merck & Co. Inc. MRK rose 0.92% to $75.87, and AbbVie Inc. ABBV fell 0.72% to $111.40. Trading volume (6.6 M) remained 338,162 below its 50-day average volume of 6.9 M. The pharmaceuticals company has gifted India another 25,600 vials of Remdesivir, which is used in the treatment of COVID-19 patients. Gilead Sciences Inc developer of antiviral drug Remdesivir had sent more than 1.5 lakh vials to India.
Gilead Sciences Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, to create a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.